Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Goodwill (2016 - 2026)

Usana Health Sciences has reported Goodwill over the past 16 years, most recently at $138.1 million for Q2 2026.

  • Quarterly Goodwill fell 4.22% to $138.1 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $138.1 million through Apr 2026, down 4.22% year-over-year, with the annual reading at $138.0 million for FY2026, 4.3% down from the prior year.
  • Goodwill was $138.1 million for Q2 2026 at Usana Health Sciences, roughly flat from $138.0 million in the prior quarter.
  • Over five years, Goodwill peaked at $144.3 million in Q3 2025 and troughed at $582000.0 in Q3 2022.
  • The 5-year median for Goodwill is $17.4 million (2022), against an average of $57.0 million.
  • Year-over-year, Goodwill plummeted 96.67% in 2022 and then soared 2796.74% in 2023.
  • A 5-year view of Goodwill shows it stood at $17.4 million in 2022, then dropped by 1.53% to $17.1 million in 2023, then surged by 742.99% to $144.2 million in 2024, then grew by 0.08% to $144.3 million in 2025, then dropped by 4.27% to $138.1 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Goodwill are $138.1 million (Q2 2026), $138.0 million (Q1 2026), and $144.3 million (Q3 2025).